Allergy Blood Tests Explained: IgE, RAST, and ImmunoCAP

Allergy blood tests measure the immune system's specific antibody responses to allergens, offering clinicians a reliable tool for identifying sensitization without exposing patients to live allergens. This page covers the three principal test types — total IgE, RAST, and ImmunoCAP — explaining the underlying mechanism, clinical scenarios where each applies, and the criteria that guide test selection. Understanding these distinctions matters because misinterpreting results remains one of the most common sources of over-diagnosis and unnecessary allergen avoidance in allergy practice.

Definition and scope

Allergy blood testing refers to laboratory-based assays that quantify immunoglobulin E (IgE) antibodies in a blood sample drawn from a patient. IgE is the antibody class central to Type I hypersensitivity reactions — the mechanism underlying most allergic responses including allergy symptoms such as urticaria, rhinitis, and anaphylaxis.

Three test categories define the landscape:

Total serum IgE — measures the aggregate IgE concentration across all specificities, expressed in international units per milliliter (IU/mL). A normal reference range for adults is approximately 0–100 IU/mL, though laboratories set thresholds individually (American Academy of Allergy, Asthma & Immunology, AAAAI).
RAST (RadioAllergoSorbent Test) — a first-generation specific IgE assay that uses a radiolabeled anti-IgE antibody bound to an allergen-coated disk. RAST was introduced commercially in the 1970s and has been largely superseded in clinical practice by fluorescent enzyme immunoassay platforms.
ImmunoCAP (specific IgE fluorescent enzyme immunoassay) — the current clinical standard for specific IgE quantification, developed by Phadia (now part of Thermo Fisher Scientific). ImmunoCAP uses a cellulose sponge carrier covalently bound to allergen, enabling a broader dynamic range and lower detection limits than RAST.

The U.S. Food and Drug Administration (FDA) classifies in vitro allergy diagnostic tests as Class II medical devices under 21 CFR Part 866, requiring 510(k) clearance for marketed platforms. The regulatory context governing allergy testing practices includes both FDA device oversight and laboratory requirements under the Clinical Laboratory Improvement Amendments (CLIA), administered by the Centers for Medicare & Medicaid Services (CMS).

How it works

All specific IgE blood tests follow a common immunoassay logic:

Sample collection — A venous blood draw yields serum or plasma; no fasting is required and antihistamine use does not interfere, unlike skin prick testing.
Allergen-antibody binding — The patient's serum is incubated with a solid phase carrying a defined allergen extract or molecular allergen component. Specific IgE antibodies in the serum bind to their target allergen.
Detection — A labeled anti-IgE antibody (fluorescent in ImmunoCAP; radioactive in original RAST) is applied. The signal intensity is proportional to the amount of bound specific IgE.
Quantification — ImmunoCAP reports results in kilounits of allergen-specific IgE per liter (kUA/L), using a standardized 6-class scale ranging from Class 0 (< 0.10 kUA/L, undetectable) to Class 6 (≥ 100 kUA/L, very high), per the CAP classification scheme published by Phadia/Thermo Fisher and referenced in AAAAI practice parameters.
Interpretation — A result above the 0.35 kUA/L detection threshold indicates sensitization, not necessarily clinical allergy; correlation with patient history is required.

ImmunoCAP demonstrates a reported coefficient of variation below 10% across its concentration range, a performance characteristic that contributes to its adoption as the reference method in AAAAI and Joint Task Force practice parameters (Joint Task Force on Practice Parameters, JTFPP, Allergy Diagnostic Testing: An Updated Practice Parameter, Annals of Allergy, Asthma & Immunology, 2008).

Molecular component-resolved diagnostics (CRD) extend ImmunoCAP methodology by testing against purified or recombinant protein components — for example, Ara h 2 for peanut allergy — rather than crude extracts, improving positive predictive value in food allergy assessment according to published AAAAI position papers.

Common scenarios

Allergy blood tests are ordered across a defined set of clinical situations:

Dermatographism or extensive eczema — Patients with eczema and atopic dermatitis or dermatographism cannot undergo skin prick testing because baseline skin reactivity confounds results; blood testing provides the only reliable in-office IgE measurement.
Anticoagulant therapy — Patients on warfarin or direct oral anticoagulants are candidates for blood-based testing to avoid procedural skin risks.
Pediatric populations — Blood testing is often preferred in young children where skin testing cooperation is limited; allergies in children are assessed using age-adjusted IgE reference ranges.
Food allergy evaluation — Specific IgE levels for foods such as peanut, milk, egg, and tree nuts correlate probabilistically with reaction risk; threshold values for 95% positive predictive value have been published for selected foods in pediatric populations (AAAAI practice parameters).
Aeroallergen panels — Multi-allergen panels covering grasses, trees, molds, dust mites, and animal danders are used in the workup of allergic rhinitis and allergic asthma.
Occupational exposure — Workers with suspected occupational allergies may require specific IgE testing when workplace allergen removal is impractical during evaluation.

The allergy testing methods landscape also includes patch testing and oral food challenges; blood tests occupy a distinct position within the overall allergy diagnosis process.

Decision boundaries

Choosing between blood-based and skin-based testing — and among blood test platforms — depends on structured clinical criteria. The following boundaries are drawn from AAAAI and JTFPP guidance:

Blood test vs. skin prick test

Factor	Favors blood test	Favors skin prick test
Medication interference	Antihistamines in use	Antihistamines discontinued ≥ 5 days
Skin condition	Active eczema, dermatographism	Intact skin
Age	Under 2 years (limited cooperation)	Older cooperative patients
Allergen availability	Standardized extract unavailable	Standardized extract available
Sensitivity requirement	Slightly lower sensitivity acceptable	Higher sensitivity preferred

Interpreting quantitative results

A positive specific IgE value indicates sensitization — the presence of IgE antibodies — but does not independently confirm clinical reactivity. The AAAAI estimates that 30–40% of sensitized individuals show no clinical symptoms upon allergen exposure, a phenomenon documented in population-based studies. For this reason, result interpretation requires integration with clinical history and, in food allergy, may require an oral food challenge for definitive diagnosis.

Class thresholds and clinical significance

Class 0–1 (< 0.35–0.70 kUA/L): Negative to equivocal; clinical significance low
Class 2–3 (0.70–3.50 kUA/L): Low to moderate sensitization; symptom correlation essential
Class 4–6 (3.50 kUA/L and above): Moderate to very high sensitization; higher probability of clinical reactivity but not diagnostic alone

Total IgE limitations

Elevated total IgE above 100 IU/mL is associated with atopic disease but lacks specificity; parasitic infection, certain immunodeficiencies, and non-allergic inflammatory conditions also elevate total IgE. The total IgE result therefore functions as a screening signal rather than a diagnostic conclusion.

The full allergy diagnosis process — available through the allergy authority resource index — situates blood testing within a multi-step evaluation that includes clinical history, physical examination, and when appropriate, supervised allergen challenges. Decision boundaries for immunotherapy candidacy, which may be informed by specific IgE profiles, are addressed under allergy immunotherapy guidelines issued by the AAAAI and JTFPP.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)